Short Interest in CapsoVision, Inc. (NASDAQ:CV) Increases By 281.0%

CapsoVision, Inc. (NASDAQ:CV) was the recipient of a large growth in short interest during the month of January. As of January 30th, there was short interest totaling 357,735 shares, a growth of 281.0% from the January 15th total of 93,892 shares. Based on an average daily volume of 468,270 shares, the days-to-cover ratio is presently 0.8 days. Currently, 0.8% of the shares of the company are short sold. Currently, 0.8% of the shares of the company are short sold. Based on an average daily volume of 468,270 shares, the days-to-cover ratio is presently 0.8 days.

Institutional Trading of CapsoVision

Institutional investors and hedge funds have recently made changes to their positions in the business. New York State Common Retirement Fund acquired a new position in shares of CapsoVision during the 3rd quarter worth approximately $34,000. Citadel Advisors LLC acquired a new position in CapsoVision during the third quarter worth $115,000. Geode Capital Management LLC lifted its holdings in CapsoVision by 34.1% during the fourth quarter. Geode Capital Management LLC now owns 154,264 shares of the company’s stock valued at $1,649,000 after purchasing an additional 39,231 shares in the last quarter. Finally, Deutsche Bank AG acquired a new stake in shares of CapsoVision in the fourth quarter valued at about $47,000.

CapsoVision Stock Up 3.0%

Shares of CV stock traded up $0.14 on Wednesday, hitting $4.83. The company had a trading volume of 226,097 shares, compared to its average volume of 443,321. CapsoVision has a twelve month low of $3.43 and a twelve month high of $15.37. The firm has a market cap of $226.24 million and a P/E ratio of -2.21. The company has a 50-day moving average price of $8.37 and a 200-day moving average price of $5.89.

CapsoVision (NASDAQ:CV) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.03). The business had revenue of $3.54 million during the quarter.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Wall Street Zen upgraded shares of CapsoVision to a “hold” rating in a research report on Saturday, January 10th. Weiss Ratings reiterated a “sell (e)” rating on shares of CapsoVision in a research note on Monday, December 29th. Roth Mkm set a $7.00 price objective on CapsoVision in a research note on Tuesday, November 4th. Zacks Research raised CapsoVision to a “hold” rating in a report on Wednesday, November 5th. Finally, Benchmark reiterated a “speculative buy” rating on shares of CapsoVision in a research report on Friday, November 14th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $6.00.

CapsoVision Company Profile

CapsoVision, Inc (NASDAQ: CV) is a medical device company specializing in advanced capsule endoscopy systems for gastrointestinal diagnostics. The company’s flagship product, the CapsoCam® Plus System, features a swallowable, tether-free capsule equipped with four side-viewing cameras that capture high-resolution, 360-degree images of the small intestine. By storing images internally rather than transmitting data wirelessly, CapsoCam Plus enables patients to maintain normal daily activities during the procedure and reduces the risk of signal loss or image drop-out.

In addition to its capsule hardware, CapsoVision offers CapsoCloud®, a secure, cloud-based platform that streamlines image retrieval, storage and reporting.